Latanoprost - Laboratoires Thea
Alternative Names: IYUZEH; LUDPF; Monopost; Monoprost; Non-preserved latanoprost - Laboratoires TheaLatest Information Update: 28 Sep 2023
At a glance
- Originator Laboratoires Thea
- Developer Clermont Pharmaceuticals; Laboratoires Thea
- Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glaucoma; Ocular hypertension
Most Recent Events
- 26 Sep 2023 Launched for Glaucoma in USA (Ophthalmic)
- 26 Sep 2023 Launched for Ocular hypertension in USA (Ophthalmic)
- 03 Mar 2023 Thea Pharma announces intention to launch Latanoprost (IYUZEH™) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension in USA in second half of 2023